# Measured binders of a kinase target: ALK in one query

> One BioQ query for ALK returns exact ChEMBL measurements, 17 known drugs and 6477 IC50 values from several sources, as of 2026-11-06, in 1.96 engine seconds.

Data as of 2026-11-06 · Published 2026-11-07 · Updated 2026-11-06 · https://bioq.bio/blog/en/howto-every-measured-binder-of-alk

![BioQ results page for the query ALK showing the strongest exactly measured compounds and the drugs known for the gene.](https://bioq.bio/blog/img/howto-every-measured-binder-of-alk/en/hero.webp)

Typing ALK into BioQ returns the measured binders of a kinase target in one pass. The result has three views: the strongest exact ChEMBL measurements (10 shown), 17 known drugs ordered by clinical stage, and 6477 IC50 measurements from several sources. The data are as of 2026-11-06.

## What we asked: the measured binders of a kinase target

The task is a common one. You have a kinase, here ALK, and you want to know which compounds have been measured against it, how strongly, and which of them are drugs. You also want to know whether the evidence is a direct measurement or only an annotation.

The manual route means opening ChEMBL for the activity records, a target database for the drug list, a binding database for extra IC50 values, and a trial registry to see which drugs are in the clinic. Then you reconcile compound names by hand, because the same molecule appears as a ChEMBL ID in one place and a trade name in another.

In BioQ the same task is one query: `ALK`. The engine ran 3 queries across 3 distinct resources in 1.96 seconds in total. That is engine time only. It does not include the time you spend reading the output.

## What BioQ returned

The first block lists the strongest exactly measured compounds on ALK from the current ChEMBL release. Only exact (=) measurements count. Censored values (> or <) are excluded, so a compound reported only as "IC50 below some limit" cannot take a place here.

| Compound | ChEMBL ID | Best pChEMBL | Type | Exact measurements | Max clinical stage |
|---|---|---|---|---|---|
| — | CHEMBL3286823 | 10 | KI | 3 | — |
| — | CHEMBL3286825 | 10 | KI | 3 | — |
| — | CHEMBL5593687 | 10 | IC50 | 1 | — |
| — | CHEMBL3286826 | 9.96 | IC50 | 2 | — |
| — | CHEMBL3286828 | 9.92 | KI | 3 | — |
| — | CHEMBL3824308 | 9.92 | IC50 | 1 | — |
| — | CHEMBL3892880 | 9.78 | IC50 | 1 | — |
| — | CHEMBL3687205 | 9.77 | IC50 | 2 | — |
| — | CHEMBL3822611 | 9.74 | IC50 | 1 | — |
| — | CHEMBL3823235 | 9.74 | IC50 | 1 | — |

Three compounds share the top pChEMBL of 10.0, two of them from Ki data and one from an IC50. None of the ten has a clinical stage in this view, which shows as a dash. The top of the exact-potency list is therefore made up of research compounds, not approved drugs.

The second block turns to the drugs known for ALK, ordered by clinical stage. BioQ found 17 and shows 8.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Ceritinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9.7 | IC50 | 30 |
| Lorlatinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9.7 | IC50 | 51 |
| Brigatinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9.43 | IC50 | 34 |
| Crizotinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9.33 | EC50 | 94 |
| Alectinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9.23 | IC50 | 62 |
| Entrectinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | 9 | KI | 33 |
| Alectinib Hydrochloride | APPROVAL | ALK tyrosine kinase receptor inhibitor | — | — | 0 |
| Ensartinib | APPROVAL | ALK tyrosine kinase receptor inhibitor | — | — | 23 |

![BioQ drug table for ALK listing approved inhibitors with mechanism, best exact pChEMBL, measurement type and trial count](https://bioq.bio/blog/img/howto-every-measured-binder-of-alk/en/drugs.webp)
*The drugs block for ALK: stage, mechanism, exact potency and trials by name*

Ceritinib and lorlatinib both show a top exact pChEMBL of 9.7 from IC50 data. Brigatinib follows at 9.43, crizotinib at 9.33 and alectinib at 9.23. Note the Type column. The crizotinib value is an EC50, a cell-based readout, and the entrectinib value of 9.0 is a Ki. These are different quantities, so the numbers are not strictly like for like. Alectinib Hydrochloride and Ensartinib have no exact pChEMBL in this view. The trial count is a match by drug name, so alectinib hydrochloride shows 0 while ensartinib shows 23.

The third block is the raw IC50 layer. BioQ holds 6477 IC50 measurements for ALK across ChEMBL, DrugCentral, Guide to Pharmacology and BindingDB, and shows 8.

| Compound | Type | Value | Unit | Assay type | Source |
|---|---|---|---|---|---|
| CHEMBL3397300 | IC50 | 0.07 | nM | B | chembl |
| CHEMBL5593687 | IC50 | 0.1 | nM | B | chembl |
| CHEMBL3286826 | IC50 | 0.11 | nM | B | chembl |
| CHEMBL3824308 | IC50 | 0.12 | nM | B | chembl |
| tae-684 | IC50 | 0.15 | nM | B | chembl |
| CHEMBL3892880 | IC50 | 0.168 | nM | B | chembl |
| us9126931, 277 | IC50 | 0.168 | nM | — | bindingdb |
| CHEMBL3687205 | IC50 | 0.17 | nM | B | chembl |

This table is a page of the matches, not a ranking. Even so, CHEMBL5593687, CHEMBL3286826, CHEMBL3824308, CHEMBL3892880 and CHEMBL3687205 also appear in the strongest-compound table. The two views agree on which compounds sit at the potent end. One row comes from BindingDB, and the source column tells you which database each value came from.

## What it means and how to read it

Read the three blocks together, not one at a time.

- **Strongest compounds.** Use this list to see how potent the chemistry against ALK gets in public data. It does not tell you which compounds are drugs.
- **Drug list.** Use this to place the known ALK inhibitors, such as lorlatinib, crizotinib and alectinib, on a common potency scale. Check the Type column before you compare two values.
- **IC50 layer.** Use this to inspect individual measurements. The Assay type column separates biochemical records (B) from other formats, and a blank means the source did not give one.

Higher pChEMBL means stronger potency. It is the negative log10 of the molar value, so one unit is a tenfold change. The difference between 9.7 and 9.43 is therefore a small multiple, not a different class of compound.

Sensible next steps:

1. Open the ChEMBL ID of any compound that interests you and read the assay description behind its exact measurements. A single measurement (n = 1) is weaker evidence than three.
2. For kinase selectivity, run the same query on the off-target kinases you care about and compare the compounds that recur. One ALK query gives potency on ALK only.
3. For drugs with no exact pChEMBL in the list, such as Ensartinib, go to the IC50 layer and filter by name.

## How to reproduce it in BioQ

1. Open BioQ and paste the query below into the search box.
2. Read the strongest-compound block first and note which entries have a clinical stage.
3. Move to the drug block and check the Type column before comparing potency values.
4. Open the IC50 block to see how many measurements exist in total and which database each came from.

```text
ALK
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DALK)

5. Repeat with another kinase gene symbol to build a comparison across targets.

Every block names its source and release, so you can cite ChEMBL or the other resources directly.

## Limits: what the data do not show

- **Exact values only.** The strongest-compound list leaves out censored measurements. A potent compound that was reported only with a "less than" value is absent.
- **Mixed measurement types.** IC50, EC50 and Ki are different readouts. A shared pChEMBL scale puts them side by side, but it does not make them equivalent. Assay conditions such as ATP concentration, construct and cell line also differ between records.
- **Not a ranking of drugs.** Potency on ALK does not tell you how a drug behaves in patients. The data say nothing about efficacy, tolerability or dosing.
- **Trial counts by name.** The trials column matches on drug name, so it can include trials unrelated to ALK and cannot say what each trial found.
- **Page, not total.** The IC50 table shows 8 rows of 6477. Use it to inspect records, not to infer a distribution.
- **Snapshot.** Values reflect the releases named in each block as of 2026-11-06 and will change as the resources update.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (3 queries, 2.0 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/affinity`, `/drugs`

Run the same query yourself: [ALK](https://bioq.bio/login?next=%2Fapp%23q%3DALK)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`ALK`](https://bioq.bio/login?next=%2Fapp%23q%3DALK)

## Frequently asked questions

### How do I find all measured binders of ALK in one search?

Enter ALK in BioQ. It returns the strongest exactly measured compounds from ChEMBL, 17 known drugs by clinical stage, and 6477 IC50 measurements. The engine ran 3 queries in 1.96 seconds.

### Which ALK inhibitors have the highest exact pChEMBL in BioQ?

Among the drugs shown, ceritinib and lorlatinib have 9.7, both from IC50 data. Brigatinib has 9.43, crizotinib 9.33 and alectinib 9.23. The crizotinib value is an EC50, so it is not strictly comparable to the IC50 values.

### Why are censored values excluded from the strongest compounds list?

Only exact (=) measurements count, and values reported as greater or less than a limit are left out. This keeps the pChEMBL values tied to real measured numbers. Compounds that have only censored data do not appear in the list.

### How many ALK IC50 measurements does BioQ hold?

BioQ finds 6477 IC50 measurements for ALK across ChEMBL, DrugCentral, Guide to Pharmacology and BindingDB. The table shows 8 of them as a page of matches, not a ranking.

### Does a high pChEMBL mean a compound is selective for ALK?

No. The ALK query gives potency on ALK only, so selectivity needs the same query on other kinases. Compare the compounds that recur across those results.

## Sources

- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [ChEMBL, BindingDB, DrugCentral and Guide to Pharmacology binding data](https://www.ebi.ac.uk/chembl/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
